Abbvie Sculpts Position In Aesthetics Space With Allergan Acquisition
Abbvie is taking on Allergan's aesthetics portfolio as part of its $63bn takeover deal. The acquisition includes Allergan's CoolSculpt body contouring system and a new FDA-approved device for muscle strengthening.
You may also be interested in...
AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.
Promotion does not adequately communicate the diabetes drug’s indication, limits of use and risks, FDA says. It objects to distracting visuals in video and less prominent risk information. Agency had previously relayed its concerns to Lilly about Trulicity promotions.